• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Mid-Cycle Clinical and Statistical Summary - ALLOCORD

 

BLA 125413
 
Applicant: SSM Cardinal Glennon Children’s Medical Center and the St. Louis University School of Medicine, St. Louis Cord Blood Bank (SLCBB)
 
Received Date: 10/21/2011; PDUFA Goal Date: 8/20/2012
 
Clinical Reviewer: Lei Xu, Team leader: Changting Haudenschild; Branch Chief: Ilan Irony (OCTGT)
 
Statistical Reviewer: Renee Rees (OBE); Team leader (acting): Shiowjen Lee; Branch chief: Boguang Zhen
 
Chemical Name: Hematopoietic progenitor cells, cord (HPC-C)
 
Trade Name: AlloCORD
 
Proposed Indications: For use  in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.
 
Final formulation: Each unit of AlloCORD contains a minimum of 5 x 108 total nucleated cells (TNC) with a minimum of 1.25 x 106 viable CD34+ cells, suspended in 10% dimethyl sulfoxide (DMSO), and 1% dextran 40, at the time of cryopreservation
 
Dosing: The recommended minimum dose is2.5 x 107 TNC/kg at cryopreservation, matching for at least 4 of 6 HLA-A antigens, HLA-B antigens, and HLA-DRB1 alleles is recommended.
 
Route of Administration: IV infusion
  • Adult: begin infusion at 100ml /hour and increase the rate as tolerated
  • Children: begin infusion at 1ml/kg/hour and increase as tolerated
 
Cord Blood Collection Sites: 33 sites:
  • 29 in metropolitan St. Louis region (eastern Missouri and southern Illinois)
  • 4 in Kansas City region
 
Collection time range (submitted dataset): 1996-2011
 
Registered patients in dataset: 1055 single-unit recipients; 75 multi-unit recipients (mostly 2 units)
 
 
Mid-Cycle Summary
 
The applicant applied for licensure of its cord blood product indicated for use  in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. The applicant referred to the COBLT data and the docket data to support the efficacy of its product. The applicant submitted a dataset of 1130 cord blood recipients (1055 subjects with single unit infusions and 75 subjects with more than one unit infusions) to support the safety of  its product. These units of the cord blood were collected from 33 collection sites in the States of Missouri, Illinois and Kansas from 1996 to 2011. The following summarizes our joint preliminary data analyses from the raw dataset provided by the applicant.
 
1.     The FDA data analyses are based on an incomplete dataset of patients who received a single unit of the product. Missing data occur in various degrees for the different variables; this is largely due to the retrospective and passive nature of data collection. In addition, multiple miscodings and inconsistencies within the dataset have been identified.
2.     The main age category consists of pediatric patients (1 month to < 18 years) - 52% and young adults (18 to <65) - 44%. Neonates (1 month or younger) and geriatric patients (≥ 65) are represented in a small proportion (3.5%) (Table 1).
3.     82.9% of cord blood units are given to patients with hematological malignancies, and 7.1% of cord blood units are given to patients with immunodeficiency. Other categories include metabolic disorders, bone marrow failure, hemoglobinopathy and autoimmune diseases (Table 1).
4.     Among the 644 recipients with information on the number of total nuclear cells infused, the median dose is 4.4 x 107 /kg (Table 1).
5.     The data regarding HLA match are missing in the raw data sheet (Table 2).
6.     Hematopoietic recovery of neutrophil and platelet are calculated from this retrospective dataset. They are consistent with those from the COBLT study and the Docket (Table 3).
7.     Overall reported death rate is 51% (392/764). The rate is compatible with docket data, as is the rate of death < 100 days post-transplant. The main causes of death include primary diseases, infection, pulmonary etiologies, GVHD, graft failure, and organ failure. Death due to graft failure or GVHD accounts for 5.1% and 4.6% of deaths, respectively (Table 4).
8.     About 54% of 742 patients with reported information developed acute GVHD, and 71% with mild grade (≤ grade 2) (Table 5).
9.     Infusion reactions occurred in 18% of 453 patients. The most common reaction is hypertension, followed by other relatively common ones, including nausea, vomiting, bradycardia, headache, and chest pain (Table 6).
10. The preliminary analyses of the safety outcomes areroughly compatible with Docket/public data. Therefore, the current assessment is that a post-market study (REMS or PMR) may not be necessary. However, the final review may suggest otherwise.
  
Table 1. Demographic Characteristics

Category
St. Louis
Docket
Number of patients
N=1055 (%)
N=1572 (%)
Age
 
 
 
 
Median (range)
16 yrs (25 d-73 yrs)
6 yrs (<1-66 yrs)
< 1 month
2 (0.19)
 
1 month – < 18 years
549 (52)
1296 (82)
18 - < 65 years
469 (44)
276 (17.7)
≥ 65 years
35 (3.3)
 
Gender
Male
601 (57)
 
Female
454 (43)
 
Race/Ethnicity
Caucasian
African American
Hispanic
Asian
American Indian
Other / Unknown
669 (63.4)
88 (8.3)
9 (0.9)
27 (2.6)
4 (0.3)
258 (24.4)
 
Diagnosis
 
Malignancy
Metabolic disorder
Immunodeficiency
Marrow failure
Hemoglobinopathy
Autoimmune disorder
Other
755 (71.5)
48 (4.6)
73 (7.1)
36 (3.4)
22 (2.0)
1 (1.0)
120 (11.4)
1103 (70.2)
140 (8.9)
96 (6.1)
114 (7.3)
8 (0.5)
 
111 (7.0%)
Median dose/kg (TNC x 107)
4.4 (0.03-553.9)
(N = 644)
5.3 (0.7-74)

 
Table 2. HLA Match

Category
St. Louis
Docket
HLA Match
3/6
Data Missing (N=?)
55 (3.5)
4/6
 
723 (46)
5/6
 
 
6/6
 
170 (10.8)
Unknown
 
11 (0.7%)

 
 
Table 3. Hematopoietic recovery in patients transplanted with TNC Dose ≥2.5x107/kg (ANC: neutrophil, PLT: Platelet)

Data Source
St. Louis
COBLT
Docket
Study Design
Retrospective
Prospective
Retrospective
Number of Patients
N=282-516
N=324
N=1299
ANC recovery at Day 42 (%)
77
76
77
PLT recovery at Day 100 (20k) (%)
76
57
 
Platelet recovery at Day 100 (50k) (%)
70
46
45
Median time in days to ANC recovery (>500)
20 (0- 1122)
(N = 516)
27
25
Median time in days to PLT recovery (20k)
46 (0-271)
(N = 359)
90
 
Median time in days to PLT recovery (50k)
 
51 (0-302)
(N = 337)
113
122

 
Table 4. Safety Outcome: Death (Primary Cause)

Death Rate and Cause of Death
St. Louis
Docket
Total Number of patients
N=764 (%)
N=1572 (%)
Total Number of Deaths
392 (51)
838 (53.3)
Death < 100 days post-transplant
180 (23.6%)
469 (29.8)
Cause of Death
(N=391)
 
       Primary disease
138 (35.2)
 
       Infection
79 (20.2)
(7.8)
       Pulmonary
36 (9.2)
 
       Organ failure
16 (4.1)
(6.5)
       Graft Failure
18 (4.6)
(3.7)
       GVHD
24 (5.1)
 
       Secondary malignancy
4 (1.0)
 
       Other
77 (19.6)
 

 
 
Table 5. Safety Outcomes: GVHD

GVHD
St. Louis
Docket
Number of Patients
N=742 (%)
1381
Acute GVHD
403 (54)
1569 (88)
Grade
0
1
2
3
4
Unknown
 
 
120 (30)
164 (41)
74 (18)
39 (9.8)
3 (0.8)
 
451 (33)
347 (25)
314 (23)
176 (13)
93 (6)
 

 
 
Table 6. Safety Outcome: Infusion Reactions

Infusion Reactions
St. Louis
COBLT
Number of Patients
or Units of Infusion
Patient
N=453 (%)
Infusion
N=523 (%)
Any Infusion Reaction
82 (18)
65.4
Hypertension
59 (72)
46.5
Nausea
16 (19.5)
14.8
Vomiting
13 (15.9)
15.7
Brachycardia
12 (14.6)
10.3
Headache
7 (8.5)
 
Chest pain
6 (7.3)
 
Hypoxia
2 (2.4)
2.9
Shortness of breath
3 (3.7)
1.7
Chills
2 (2.4)
1.3
Hemoglobinuria
2 (2.4)
1.9
Tachycardia
3 (3.7)
5.2
Hypotension
2 (2.4)
2.9
Hives
 
 
Rigor
3 (3.7)
 
Fever
6 (7.3)
5.5
Other
9 (11)